CARGO Therapeutics, Inc. (NASDAQ:CRGX – Get Free Report) CEO Gina Chapman sold 2,975 shares of the firm’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $25.03, for a total value of $74,464.25. Following the completion of the transaction, the chief executive officer now owns 103,905 shares of the company’s stock, valued at approximately $2,600,742.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
CARGO Therapeutics Price Performance
NASDAQ:CRGX opened at $23.85 on Friday. The firm has a 50 day simple moving average of $18.09 and a 200-day simple moving average of $19.48. CARGO Therapeutics, Inc. has a 1-year low of $13.14 and a 1-year high of $33.92.
CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.04. As a group, research analysts expect that CARGO Therapeutics, Inc. will post -4.37 EPS for the current year.
Analysts Set New Price Targets
Check Out Our Latest Stock Report on CRGX
Hedge Funds Weigh In On CARGO Therapeutics
Several institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. acquired a new stake in CARGO Therapeutics in the 1st quarter worth about $48,000. American International Group Inc. acquired a new stake in shares of CARGO Therapeutics in the first quarter worth approximately $237,000. BNP Paribas Financial Markets purchased a new stake in CARGO Therapeutics in the first quarter valued at approximately $238,000. California State Teachers Retirement System acquired a new position in CARGO Therapeutics during the first quarter worth approximately $337,000. Finally, Rhumbline Advisers raised its stake in CARGO Therapeutics by 14.0% during the second quarter. Rhumbline Advisers now owns 30,639 shares of the company’s stock worth $503,000 after purchasing an additional 3,765 shares during the period. 93.16% of the stock is currently owned by institutional investors and hedge funds.
CARGO Therapeutics Company Profile
CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
Read More
- Five stocks we like better than CARGO Therapeutics
- Why Are These Companies Considered Blue Chips?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Insider Trades May Not Tell You What You Think
- MarketBeat Week in Review – 9/16 – 9/20
- How is Compound Interest Calculated?
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for CARGO Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CARGO Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.